SCHEMBL350506

SCHEMBL350506

Cc1cccc(C(=O)O)c1I

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.63
KDM4E B2RXH2 4/20 0.63
HPGD P15428 3/20 0.63
HSD17B10 Q99714 2/20 0.63
MYC P01106 1/20 0.57
CYP3A4 P08684 2/20 0.53
CYP2C9 P11712 2/20 0.53
KMT2A Q03164 2/20 0.53
POLB P06746 2/20 0.52
NAPRT Q6XQN6 2/20 0.50
ALOX15 P16050 2/20 0.50
MEN1 O00255 1/20 0.50
AKR1B10 O60218 1/20 0.50
TRPA1 O75762 1/20 0.50
ABCB11 O95342 1/20 0.50
DHFR P00374 1/20 0.50
LMNA P02545 1/20 0.50
MPO P05164 1/20 0.50
CYP1A2 P05177 1/20 0.50
CHRM1 P11229 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2443197 0.85 ALDH1A1 (0.60) ALDH1A1KDM4EHPGDHSD17B10KMT2A
SCHEMBL4067363 0.84 HPGD (0.50) ALDH1A1KDM4EHPGDHSD17B10MYC
Hydrochloric Acid SCHEMBL28309734 0.83 ALDH1A1 (0.57) ALDH1A1KDM4EHPGDHSD17B10KMT2A
SCHEMBL5841858 0.83 ALDH1A1 (0.48) ALDH1A1KDM4EHPGDHSD17B10MYC
SCHEMBL4523553 0.83 MYC (0.48) ALDH1A1KDM4EHPGDHSD17B10MYC
SCHEMBL3161423 0.79 TSHR (0.50) ALDH1A1KDM4EHPGDHSD17B10MYC
SCHEMBL4528516 0.79 KMT2A (0.50) ALDH1A1KDM4EHPGDHSD17B10MYC
SCHEMBL4534798 0.79 PLK1 (0.50) ALDH1A1KDM4EHPGDHSD17B10MYC
SCHEMBL19834641 0.79 AKR1C3 (0.53) ALDH1A1KDM4EHPGDHSD17B10MYC
SCHEMBL608549 0.79 ALDH1A1 (0.52) ALDH1A1KDM4EHPGDHSD17B10KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118184679-A Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material 中国石油天然气股份有限公司 2024-06-14 CN claimed
CN-116789667-A Planar triarylamine molecule and synthesis method thereof 天津大学 2023-09-22 CN claimed
CN-113731506-B Method for assisting palladium-catalyzed fatty aldehyde C-H arylation reaction by calix [4] arene amide compound 常州大学 2023-05-26 CN claimed
US-10099981-B2 Methods for meta-arylation of aromatic alcohols UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2018-10-16 US claimed
CN-103224482-A Isocoumarin compound, derivatives and synthesis method thereof UNIV SHANGHAI JIAOTONG 2013-07-31 CN claimed
WO-2006021974-A1 A PROCESS FOR SYNTHESIZING DIOL (VIII)-AN INTERMEDIATE OF MONTELUKAST SODIUM MOREPEN LABORATORIES LIMITED (IN) 2006-03-02 WO claimed
EP-4001284-B1 NOVEL BORON COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME SFC CO LTD (KR) 2025-12-10 EP disclosed
EP-3660934-B1 ORGANIC LIGHT EMITTING ELEMENT CAPABLE OF DRIVING AT LOW VOLTAGE AND HAVING HIGH EFFICIENCY AND LONG LIFE CHARACTERISTICS SFC CO LTD (KR) 2025-11-05 EP disclosed
US-12415950-B2 Boron compound and organic light emitting diode including same SFC CO., LTD. (KR) 2025-09-16 US disclosed
US-12378254-B2 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2025-08-05 US disclosed
CN-120081802-A Heterocyclic substituted benzamide derivative and application thereof 南华大学附属第一医院 2025-06-03 CN disclosed
CN-119977947-A PRMT5 inhibitor, pharmaceutical composition thereof and application of PRMT5 inhibitor in medicines 广东东阳光药业股份有限公司 2025-05-13 CN disclosed
CN-119192180-A Iridium complex of [3,2,1-de ] acridine-5, 9-diketo quinine ligand based on aza-aromatic ring modification and organic electroluminescent device 清华大学深圳国际研究生院 2024-12-27 CN disclosed
US-5100434-A Crosslinking E. I. DU PONT DE NEMOURS AND COMPANY (US) 1992-03-31 US disclosed
EP-0412848-A2 Quinoline derivatives, process for their preparation and their use as medicaments ZENECA LIMITED (GB) 1991-02-13 EP disclosed
EP-0399731-A1 Azaindenes ZENECA LIMITED (GB) 1990-11-28 EP disclosed
EP-0181526-B1 BENZOIC ACID DERIVATIVES Chugai Seiyaku Kabushiki Kaisha (JP) 1989-01-18 EP disclosed
US-4698364-A INFECTION CONTROL CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 1987-10-06 US disclosed
EP-0181526-A1 Benzoic acid derivatives Chugai Seiyaku Kabushiki Kaisha (JP) 1986-05-21 EP disclosed
US-4284619-A INJECTING RADIOIODINE COMPOUND MEDI-PHYSICS, INC. (US) 1981-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10099981-B2 Methods for meta-arylation of aromatic alcohols ADH1C, ADH1A, ADH5 ALDH1A1 11/4885KDM4E 3165/4885HPGD 685/4885
US-12378254-B2 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators HCRTR2, HCRTR1, OXTR ALDH1A1 3132/4885KDM4E 454/4885HPGD 1036/4885
US-12415950-B2 Boron compound and organic light emitting diode including same CLTB, CD79B, RB1 ALDH1A1 97/4885KDM4E 3601/4885HPGD 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.